Carvedilol, sold under the trade name Coreg, is a medication that was first approved in Belgium in 1990.

Inmagene Biopharmaceuticals has announced its intention to acquire a solo, global license with royalties for IMG-007, a non-eliminating humanized antibody targeting OX40, and IMG-004, a systemically administered BTK inhibitor with non-covalent, reversible mechanisms.

Lamotrigine, approved by the US FDA on Dec 27, 1994, is a leading anticonvulsant drug developed by GlaxoSmithKline.

European Medicines Agency Approves Review of Tisotumab Vedotin Filing for Relapsed or Spreading Cervical Cancer Therapy.

Magnesium citrate is a type of small molecule drug that is a combination of magnesium and citric acid in a 1:1 ratio.

Ascendis Pharma unveils its second TransCon™ offering: YORVIPATH® hits markets in Germany and Austria, targeting chronic hypoparathyroidism in adults.

Cefdinir, marketed under the brand name Omnicef, is a small molecule drug that acts as a penicillin-binding protein (PBP) inhibitor and a cell wall inhibitor.

NeuroBo Pharmaceuticals has received approval from the FDA for a Phase 1 clinical study of DA-1726, a new drug aimed at managing obesity.

Fluconazole is a small molecule drug used to treat various fungal infections. It is sold under the trade names Diflucan, Zoltec, and Loitin.

Halia Therapeutics has unveiled a $30 million Series C funding round to further develop their innovative range of treatments for inflammation.

Meclizine is a small molecule drug that acts as an antagonist of histamine (H1) receptors.

Bio-Thera Solutions has launched an early-stage clinical study, specifically Phase 1B/2A, for its novel monoclonal antibody, BAT6026, aimed at OX40 for treating individuals experiencing moderate to intense eczema.